US equities |
NVDA $168.89 ▼-5.47% AMD $515.21 ▲+1.30% MU $725.11 ▼-1.10% MSFT $533.16 ▼-2.20% SNDK $859.99 ▼-2.99% SPCX $143.09 ▲+0.72% AMZN $270.87 ▲+1.48% AAPL $348.51 ▼-0.62%
FinancialContent

Articles published by Harrow, Inc.

News headline image
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow to Present at Two Investor Conferences in May
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces First-Quarter 2025 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Launches VEVYE® Access for All
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Participation in Upcoming Investor Conferences
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Third Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Market Access Wins for VEVYE®
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Relaunches TRIESENCE®
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Nashville Expansion
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow to Present at Three Investor Conferences in September in New York
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow Announces Second Quarter 2024 Financial Results
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
From Harrow, Inc.
Via Business Wire
Tickers HROW
News headline image
Harrow to Attend 2024 ASRS Annual Meeting
From Harrow, Inc.
Via Business Wire
Tickers HROW